Exchange: NASDAQ·Updated 07:59 PM EDT
News
all
press releases
Femasys Secures FDA Pathway for Non-Surgical Contraceptive
FDA clears modular PMA pathway for Femasys' FemBloc, an investigational non-surgical permanent birth control device for women in the US.read more...
Benzinga
More News
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential
The U.S. Food and Drug Administration accepted Femasys’ modular premarket approval application for FemBloc, an experimental non-surgical permanent birth control technology.
Stocktwits
Femasys (NASDAQ:FEMY) Rating Increased to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Femasys from a "sell" rating to a "hold" rating in a research note on Friday...
MarketBeat
PMCB Stock Jumps 25% After Company Sells Stake In Femasys
PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.
Stocktwits
Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing
Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device.
Stocktwits
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
Femasys (FEMY) delivered earnings and revenue surprises of +11.11% and -48.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up
The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday.
Stocktwits
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
chainwire

Advertisement|Remove ads.